Abstract
We describe an Escherichia coli genetic screen that yields mutations affecting two different cellular processes: disulfide bond formation and membrane protein assembly. The mutants defective in disulfide bond formation include additional classes of dsbA and dsbB mutations. The membrane protein assembly defective mutants contain a mutation in the secA operon and three mutations in the ffs gene, which encodes 4.5S RNA. These latter mutations are the only ones to be isolated in a gene encoding a component of the bacterial signal recognition particle by screening in vivo for defects in membrane protein insertion. A sensitive method for examining membrane protein localization shows that the ffs and secA locus mutations affect membrane assembly of the polytopic membrane protein, MalF. The ffs mutations also affect the membrane insertion of the FtsQ and the AcrB proteins. Although both the ffs and the secA locus mutations interfere with membrane protein assembly, only the latter also reduces export of a protein containing a cleavable signal sequence.
This is the story of a genetic selection designed to yield mutations affecting one cellular process that instead yielded mutations in another. And, how, years later, a modification of that selection gave us the mutations we originally sought.
Approximately 10 years ago we developed a genetic selection to isolate Escherichia coli mutants defective in membrane protein assembly. The strain we used expressed a fusion of β-galactosidase to a large periplasmic domain of the cytoplasmic membrane protein MalF (1) (Fig. 1). The resulting hybrid protein was incorporated into the membrane with a portion of the β-galactosidase exported to the periplasm, a portion in the membrane, and a third portion in the cytoplasm. Not surprisingly, this protein exhibited no β-galactosidase activity (2). We anticipated that mutations in genes required for membrane protein insertion would result in localization of the β-galactosidase to the cytoplasm where it would be enzymatically active and allow growth of cells on lactose. However, selecting for Lac+ mutants of the E. coli strain expressing this fusion only yielded mutations disrupting disulfide bond formation (3). We speculated that in the wild-type background, disulfide bonds were formed in the exported portion of the β-galactosidase, thus stabilizing the transmembrane structure of the β-galactosidase and rendering it inactive. Inactivation of the disulfide bond formation pathway destabilized the transmembrane structure of β-galactosidase, allowing it to be retracted into the cytoplasm where it was enzymatically active (Fig. 1). This hypothesis was supported by the observation that adding DTT, a reductant able to break disulfide bonds, could restore β-galactosidase activity to this fusion protein (4).
With this Lac+ genetic selection, we obtained mutations in two genes required for disulfide bond formation, dsbA and dsbB (3, 5). Extensive exploitation of this genetic selection repeatedly produced phenotypically null mutants that either introduced stop codons in the gene or eliminated one of the essential cysteine residues in the two proteins. It appeared that the Lac+ selection demanded maximal levels of β-galactosidase activity, which in turn required full inactivation of the pathway for disulfide bond formation.
We were interested in carrying out a genetic structure-function analysis of DsbB and DsbA. In addition, we were seeking extragenic mutations in other genes that might cause less severe defects in disulfide bond formation. Because these goals did not seem to be achievable with the genetic selection we were using, we decided to modify our approach to find weaker mutants. Instead of selecting for Lac+ colonies, we would screen for partial restoration of β-galactosidase activity to the fusion protein. Here, we describe the collection of mutants obtained with this screening procedure. We obtained additional weaker mutations in dsbA and dsbB. In addition, we identified mutations in genes that affect membrane protein insertion, the original goal of this project. These mutations are in ffs, encoding 4.5S RNA, the RNA component of the bacterial signal recognition particle (SRP), and in gene X, encoding a protein that is cotranslationally coupled with SecA. We report on mutations isolated in SRP in a screen or selection for mutants defective in membrane protein insertion. Using a sensitive assay for membrane protein insertion (6), we show that these mutations affect the assembly of several membrane proteins.
Materials and Methods
Strains, Plasmids, Media, and Growth Conditions.
Strains and plasmids are listed in Table 1. Strains were grown at 37°C or 30°C in NZY-rich medium (6) or M63 minimal medium supplemented with d-glucose or maltose (0.2%), B1 (1 μg/ml), and MgSO4 (1 mM) (7). When needed, 5-bromo-4-chloro-3-indolyl β-d-galactopyranoside (X-Gal) was added (20 μg/ml). For the screening, colonies were grown on M63 minimal maltose X-Gal plates for 2 days at 30°C. For the β-galactosidase assay (7), cells were grown at 30°C in NZY medium containing maltose (0.2%). For the induction of the FtsQ-Propionibacterium shermania transcarboxylase (PSBT) and MalF-PSBT fusions, 0.2% l-arabinose and 0.5 mM isopropylthiogalactopyranoside were added, respectively. Antibiotics were used at the following final concentrations unless otherwise specified: ampicillin, 200 μg/ml; kanamycin, 40 μg/ml; spectinomycin, 100 μg/ml; tetracycline, 15 μg/ml; and chloramphenicol, 10 μg/ml.
Table 1.
Relevant characteristics | Reference or source | |
---|---|---|
Strain | ||
CAG18480 | MG1655 nadB51∷Tn10 | (36) |
CAG599 | F−zhg∷Tn10 lacZ (am) trp (am) pho (am) supC (ts) mal (am) rpsL | Harris D. Bernstein |
DR388 | DHB4 Δ(λattL − lom)∷bla trxC′−′lacZ argE∷Tn10 | Daniel Ritz |
EC294 | MG1655 leu∷Tn10 | David S. Weiss |
HPT57 | MC1000 phoA+ phoR− leu+ λ102D1 (malF-lacZ 102, Ampr) | This study |
HPT129 | HPT57 zih∷Tn10 | This study |
HPT130 | HPT57 fadR∷Tn10 | This study |
HPT183 | MC4100 zba-3054∷Tn10 | This study |
HPT184 | MC4100 ffs29 zba-3054∷Tn10 | This study |
HPT185 | MC4100 ffs69 zba-3054∷Tn10 | This study |
HPT186 | MC4100 ffs91 zba-3054∷Tn10 | This study |
HPT242 | JP313 zba-3054∷Tn10 | This study |
HPT244 | JP313 ffs69 zba-3054∷Tn10 | This study |
HPT265 | JP313 gene X leu∷Tn10 | This study |
JP313 | MC4100 Δ ara714 | (37) |
MC4100 | F−araD139 relA1 thi rpsL150 flbB5301 (lacU139) deoC7 ptsF25 | Laboratory collection |
RI89 | MC1000 phoA+ phoR− leu+ | (38) |
RI90 | RI89 dsbA∷Kan | (38) |
SG20253 | MG1655 zba-3054∷Tn10 | (36) |
Plasmid | ||
Litmus 28 | Cloning vector with T7 promoter, Ampr | New England Biolabs |
pAcrB576-AP | pBR acrR, acrA, -acrB576-AP, Ampr | (18) |
pAJ1077 | pBAD33-acrA, acrB, CMr | Annick Jacq |
pAM238 | pSC101 origin, Spcr | (39) |
pBAD18 | pBR origin with arabinose regulatory region, Ampr | (40) |
pBAD33-ffs | pBAD33-ffs, CMr | Harris D. Bernstein |
PBAD42-secA | PBAD42-secA, Spcr | Jan-Willem De Gier |
pCJ1 | PACYC184-gene X, CMr | Donald B. Oliver |
pDHB5700 | ptac(Kanr) | (41) |
pGJ78 series (I, J, K, and L) | MalF-PSBT fusions at positions I, J, K, and L in pBR origin plasmid under IPTG-inducible promoter, Kanr | (6) |
pHP5 | pAM238-ffs, Spcr | This study |
pHP33 | pBAD18-acrB′(BsrGI–HindIII fragment), Ampr | This study |
pHP38 | pBAD18-AcrB′-PSBTHis6 (PSBT His6 fused at NcoI site), Ampr | This study |
pHP41 | pBAD18-ftsQ, Ampr | This study |
pHP42 | pBAD18-ftsQ-PSBT, Ampr | This study |
pHP44 | pBR322-acrR′acrA acrB576-PSBT | This study |
pLMG161 | pBAD18-ftsQ, Ampr | (42) |
pMS421 | placIq, Spcr | (43) |
pNG102 | pBR322 malmalE+malF-lacZ 102, Ampr | (1) |
Strain Construction.
HPT57 was constructed in several steps. First, we made a λ transducing phage (λ 102) containing the malF-lacZ 102 fusion under the promoter for the malEFG operon. We cloned the AflIII–DraI fragment of pDHB5700 into λ cI857 Sam7 (N6-methyladenine-free, New England Biolabs) cut with BsiWI/XbaI to generate λ DBK733. This λ has homology to pBR322 near the replicative origin and in the C-terminal part of the bla. DNA from pNG102 was recombined onto λ DBK733 replacing the kanamycin-resistance gene with the malE promoter, malE, the malF-LacZ fusion 102 and a complete bla gene to generate λ 102. In a second step, strain RI 90 (dsbA-) was lysogenized by λ 102 at 30°C as ampicillin-resistant strains that exhibited blue color on NZY plates containing X-Gal. The order of genetic markers in the lysogen is gal-mod-attL-cIts-malF′-lacZ102-bla-attR. In the third step, the prophage was stabilized to prevent loss in later manipulations by deleting one of the attachment sites. The lysogens were grown anaerobically at 42°C on NZY plates containing ampicillin (25 μg/ml), X-Gal, and potassium chlorate (0.2%), the latter selecting for inactivation of the mod gene. Under anaerobic conditions, nitrate reductase reduces chlorate to chlorite, lethal to the cells. A mutation/deletion in the modABCD operon causes resistance to chlorate because of a defect in the uptake of molybdate necessary for the assembly and function of nitrate reductase (8, 9). The medium and the high temperature incubation select for deletion events that remove the chromosomal region including mod, attL, and the ts cI, but leave intact bla and, therefore, also the malF-lacZ 102 fusion. Because the blue color caused by the cleavage of X-Gal by β-galactosidase does not develop under anaerobic conditions, the plates subsequently were incubated aerobically at room temperature for 1 day.
Several blue colonies that answered this selection were tested for high temperature resistance, sensitivity to phage λcI, and resistance to low level of ampicillin (25 μg/ml) but not to high levels of ampicillin (the latter to verify the presence of a single copy of the bla gene on the chromosome). Colonies with the appropriate properties were grown on M63 minimal maltose X-Gal plates and examined under the light microscope for signs of instability (e.g., variation of the blue color within a colony). A P1 lysate made on a stable strain was used to transduce the malF-lacZ 102 fusion into a dsbA+ strain (RI89) by its 100% linkage to the ampicillin-resistance marker. The newly constructed strain, HPT57, was used for the mutagenesis.
To move mutations to different strain backgrounds, we did P1 transductions as described (7). ffs alleles were moved to different strain backgrounds by using a transposon Tn10 (originally in strain SG20253) 50% linked to the ffs gene. The gene X mutation was moved to other backgrounds by using a leu∷Tn10 (originally in strain EC294) 50% linked to the wild-type secA region.
Plasmid Construction.
A 220-bp EcoRI–PstI fragment of pBAD33-ffs was ligated to pAM238 cut with EcoRI–PstI to generate pHP5. To make pHP42, we first constructed pHP41. Wild-type ftsQ was PCR amplified from pLMG161 by using primers FtsQ5′(EcoRI): 5′-AGCGAATTCTGGAACTGGCGGACTA-3′ and FtsQ3′(XbaI): 5′-TGCTCTAGATTGTTGTTCTGCCTGTG-3′. The PCR product and pBAD18 both were cut with EcoRI–XbaI and ligated to generate pHP41. The biotinylatable domain PSBT coding region was PCR-amplified from pGJ78-J by using primers Biotin5′(XbaI): 5′-TGCTCTAGAGTCGCCGGTAAGGCCGGAGA-3′ and Biotin3′(SphI): 5′-CGTGCATGCGTGCGTCAGCCGATCTTGATG-3′. This PCR product and pHP41 both were cut with XbaI–SphI and ligated to generate pHP42. To construct plasmid pHP44, we first made pHP33 by cloning the 2,951-bp BsrGI–HindIII fragment of pAJ1077 into the Acc65I/HindIII sites of pBAD18. PSBT fusion to amino acid 576 of AcrB then was constructed by first PCR-amplifying the biotinylatable domain from pGJ78-J by using primers Biotin5′(NcoI): 5′-AGGATCCATGGTTAGAGTCGCCGGTAAGGCCGGAGA-3′ and Biotin3′(His6-HindIII): 5′-GCCCAAGCTTAGTGATGGTGATGGTGATGGCCGATCTTGATGAGACCCTG-3′. The PCR fragment was cut with NcoI and HindIII, and then ligated to the 6,068-bp NcoI–HindIII fragment of pHP33 to generate pHP38. The 770-bp XcmI–HindIII fragment of pHP38 was ligated to the 6,329-bp XcmI–HindIII fragment of pAcrB576-AP to produce the final product pHP44.
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs and used as recommended by the manufacturer.
Mutagenesis and Mapping of the Mutants.
UV mutagenesis was carried out as described (7) with only minor modifications. Five milliliters of cells was irradiated by UV light (254 nm) for 80 sec. One milliliter of NZY medium then was added, and the entire culture was transferred to a red glass tube and grown at 37°C for 30 min. Appropriate amounts of cells then were plated on M63 minimal plates supplemented with maltose and X-Gal, grown at 30°C for 2 days, then stored at 4°C. Blue colonies were picked both after the 2-day 30°C incubation and after incubation at 4°C for several more days.
To map the mutations, we directly tested for linkage to candidate genes. Linkage to the dsbA and dsbB genes was determined by P1 transduction using a transposon Tn10 in strain HPT129 90% linked to the wild-type dsbA and a transposon Tn10 in strain HPT130 80% linked to the wild-type dsbB. Linkage to the secA and the secE genes was tested by P1 transduction using P1 lysates of strains EC294 and DR388 (with Tn10's linked to the wild-type copy of the two genes). Linkage to the SRP components, ffs (4.5S RNA), ffh (Fifty-Four homolog), and ftsY (SRP receptor), was tested by P1 transduction using P1 lysates made on strains with Tn10's linked to the wild-type genes: SG20253, CAG599, and CAG18480.
Pulse–Chase and Immunoprecipitation.
Pulse–chase experiments were carried out as described (10). Cells were labeled with [35S]methionine (ICN) for 20 sec, then chased for 0, 1, and 5 min. The subsequent immunoprecipitation was performed with polyclonal anti-OmpA antibody (laboratory collection). The precipitated proteins were separated on 12% SDS-polyacrylamide gel and visualized by using the Bio-Rad PhosphorImager.
Detection of the Fusion Proteins and the Biotinylated Proteins.
A 37°C NZY overnight culture was diluted 1:100 in the same medium and grown under the same condition. The MalF-PSBT fusion was induced for about one generation with 0.5 mM isopropylthiogalactopyranoside. The FtsQ-PSBT fusion was induced with 0.2% l-arabinose at the point of dilution. The AcrB-PSBT fusion is under its own promoter and expressed constitutively; therefore no inducer was needed. Whole-cell proteins were precipitated after cells reach OD600 of 0.6 with 6% trichloroacetic acid and resuspended in SDS sample buffer containing 0.7 M β-mercaptoethanol. The resuspended protein sample was incubated at 37°C for at least 1 h, separated on 10% SDS-polyacrylamide gel, and transferred onto nitrocellulose membrane by using the semidry apparatus from Bio-Rad. To detect MalF-PSBT, FtsQ-PSBT, and AcrB576-PSBT, polyclonal anti-MalF-PhoA J, anti-FtsQ (laboratory collection), and anti-AcrB antibodies (Hiroshi Nikaido, University of California, San Francisco) were used. To detect biotinylated fusion proteins, the nitrocellulose was incubated with streptavidin-horseradish peroxidase (Amersham Pharmacia). The ECL system (Amersham Pharmacia) was used for the subsequent detection following the manufacturer's instruction.
Results
Screening for Increased β-Galactosidase Activity of the malF-lacZ Fusion Strain.
We used a genetic screen that allows us to detect a range of β-galactosidase activities. After UV mutagenizing HPT57, a strain carrying the fusion in the chromosomal λatt site, we inspected colonies grown at 30°C on M63 minimal maltose plates (the fusion protein is induced by maltose) containing X-Gal for those that exhibited a less intense blue color than the Lac + derivatives (3). We also examined the plates after additional incubation at 4°C for several days, because this procedure allows development of blue color in mutant colonies that would not have been detected after the 30°C incubation. We screened more than one million UV-mutagenized colonies. Blue colonies appeared at a frequency of approximately 0.1%. Faint blue colonies were purified and they exhibited a range of blue color intensity.
We carried out P1 transduction to determine whether the blue color phenotype was caused by mutations in dsbA or dsbB. If unlinked, they then were tested for linkage to the malF-lacZ 102 fusion. P1 lysates were first made on each mutant, and the malF-lacZ fusion was transduced into the parental strain RI89 (lacking the fusion) by its 100% linkage to the ampicillin-resistance marker. Ampicillin-resistant blue transductants indicated that the mutations had altered the fusion.
One hundred and eight stable faint blue colonies were identified, and of these, 89 were studied extensively (Table 2). Among them, 27 were linked to dsbA, 20 to dsbB, and 14 to the malF-lacZ 102 fusion. We have characterized three missense mutations in dsbA altering amino acid residues other than the cysteines and two such mutations in dsbB. These mutant strains produced relatively stable proteins with altered activities. Studies on these mutants will be described elsewhere. For the remaining 28 strains, no defect in the formation of disulfide bonds (in OmpA) was found (data not shown).
Table 2.
Class | Mutation | # of mutants identified | β-galactosidase activity |
---|---|---|---|
I | dsbA and dsbB | 27 dsbA and 20 dsbB | 5–140 u.* |
II | λ102 (malF-lacZ 102) | 14 | ND |
III | ffs | 25 | 0.2–8 u.† |
Gene X | 1 | 4–5 u. | |
Unmapped | 2 | 8–11 u. |
ND, not determined.
Miller units. For reference, the wild type has β-galactosidase activity ranges from 0.05 to 0.08 units, and the dsbA or dsbB null mutants have β-galactosidase activity ranges from 120 to 180 units.
† β-galactosidase activities were quite variable. Most ffs mutants gave β-galactosidase activities between 1 and 8 units. ffs29, ffs69, and ffs91 used for subsequent studies repeatedly gave β-galactosidase activities above 1 unit.
Recalling the original goal of our genetic approach (to obtain membrane protein insertion mutants), we decided to analyze the mutations for their effects on this process. We first determined by P1 transduction linkage of mutations to ffs, ffh, and ftsY, coding for components of the bacterial SRP pathway, and secA, E, and secY, coding for components of the E. coli Sec pathway, all implicated to be involved in membrane protein insertion. (11–19).
Twenty-five of the 28 mutants had mutations linked to the ffs gene. Of the remaining three mutants, one had mutation/s linked to the secA region, and the last two remain unmapped.
The β-galactosidase phenotype of the mutation/s linked to the secA region was fully complemented by pBAD42-secA carrying only secA (data not shown). Sequencing revealed a single mutation in gene X, the first gene in the secA operon. This mutation introduces a stop codon that should truncate the gene X encoded protein after the 37th amino acid. We speculated that the mutation in gene X was affecting the expression of secA. First, the phenotypes are complemented by secA alone, but not by pCJ1 carrying gene X alone (data not shown). Second, effects on secA expression have been observed previously with a gene X mutation (20, 21). Finally, gene X does not appear to play a role in protein export (22), whereas the X mutation described here does interfere with export of a protein with a cleavable signal sequence (see below), presumably because of its effect on secA.
Although the dsbA and dsbB mutations resulted in β-galactosidase activities ranging in levels from low to near those of the dsb null, the ffs-linked mutations, the gene X mutation, and the two uncharacterized mutants all resulted in low levels of β-galactosidase activity (Table 2).
The ffs-Linked Mutations Are in the ffs Gene.
The defect in β-galactosidase activity in all of the ffs-linked mutants was fully complemented by pHP5, carrying only the ffs gene (data not shown). We sequenced ffs in all 25 ffs mutants (Fig. 2). Twenty-three had a cytosine deletion from a stretch of five cytosines near the 3′ terminus of ffs, later referred to as ffs29. One ffs mutant (ffs69) had two cytosines changed to two thymines in the same stretch of five cytosines. The last ffs mutant (ffs91) changed two cytosines to two thymines in the DNA sequence corresponding to the 3′ end of the mature 4.5S RNA. According to the predicted secondary structure of 4.5S RNA (Fig. 2) (23), the ffs29 and ffs69 mutations should disrupt the pairing of bases.
We examined the steady-state 4.5S RNA levels in the ffs mutants by a RNase protection assay (result not shown). All mutants showed decreased steady-state levels of mature form 4.5S RNA: approximately 70%, 40%, and 30% relative to the wild-type amount for ffs29, ffs91, and ffs69, respectively. In addition, ffs29 and ffs69 mutants also produce a 4.5S RNA form that is larger than the mature form 114-nt size, possibly the precursor form of the 4.5S RNA. We suspect that the reduced amount of the mature form 4.5S RNA is responsible for the membrane insertion defect of the ffs mutants.
The ffs Mutants Are Defective in Membrane Protein Insertion of MalF.
Given the nature of our genetic screening system and reports linking bacterial SRP to membrane protein insertion (11, 13, 16, 18), we suspected that the ffs mutations affected membrane insertion of the MalF-LacZ fusion protein (see Fig. 1). We expected that the defect in membrane protein assembly might be quite weak because of the low levels of β-galactosidase in the ffs mutants.
To compensate for the weak defect of the ffs mutants, we used a sensitive assay for membrane protein insertion defects developed previously in this laboratory (6). In this assay, a biotinylatable domain (80 aa in size) from the 1.3S subunit of PSBT is fused to a periplasmic domain of a membrane protein. This domain, if retained in the cytoplasm, is biotinylated by biotin ligase, an enzyme in E. coli cytoplasm. However, we had shown that, if efficiently exported, the domain is unbiotinylated. When cells had an export defect (e.g., a secE mutation), the periplasmic MalF-PSBT fusion proteins now were biotinylated because of the cytoplasmic localization of the fusion. This was true even in strains with only defects in the kinetics of export. In these strains, even though the PSBT domain ultimately is translocated across the membrane, it is resident in the cytoplasm long enough to allow biotinylation. In contrast to periplasmic fusions, when the PSBT domain is fused to a cytoplasmic domain of a membrane protein (cytoplasmic fusion), it is biotinylated under all conditions. Our earlier experiments used MalF; thus we had available a series of PSBT fusions to various positions in MalF (6). To test for membrane protein insertion defects, plasmid series pGJ78 I and J (periplasmic fusions), and K and L (cytoplasmic fusions) were expressed in the wild-type (HPT183) and the ffs mutant strains (HPT184–186) and the biotinylation state of the fusion proteins was examined.
The periplasmic fusions, which remained unbiotinylated in the wild-type background, all were biotinylated in the ffs mutants (Fig. 3). Because the ffs mutants do not have a secretion defect (see below), these experiments suggest that the MalF-PSBT periplasmic fusion proteins are incorporated into the membrane at a slower rate in the ffs mutants than in the wild type, thus allowing the attached PSBT domain to be biotinylated. In this assay, ffs69 appears to elicit the strongest defect. The control cytoplasmic MalF-PSBT fusions were heavily biotinylated in all strain backgrounds.
We next wanted to compare a mutation affecting SRP and one affecting the Sec machinery in terms of their effects on protein translocation across the membrane and membrane protein insertion. We chose the ffs69 mutation and the gene X mutation as they had comparable effects on the activity of the MalF-LacZ fusion protein (Table 2). We examined the effects of the two mutations on the translocation of a cell envelope protein with a signal sequence (OmpA) and on membrane protein insertion monitoring the biotinylation state of the MalF-PSBT fusions. The mutations had similar effects on the biotinylation of the MalF-PBST periplasmic fusions (data not shown). In contrast, the gene X mutant had a significant defect in signal sequence cleavage of the OmpA protein, an indication of a translocation defect, whereas the ffs mutant had no measurable effect on this process (Fig. 4).
The ffs Mutants Are Defective in the Insertion of Membrane Proteins FtsQ and AcrB.
Because the MalF-β-galactosidase fusion was used to detect the ffs mutations in the first place, it seemed possible that these mutations were affecting only the MalF. To show that the ffs mutations were affecting membrane protein insertion in general, we extended the use of the biotinylation assay to two other membrane proteins: FtsQ and AcrB.
FtsQ, a bitopic protein involved in cell division in E. coli, resides in the inner membrane with the amino terminus in the cytoplasm and the carboxyl terminus in the periplasm (24). The biotinylatable domain PSBT was fused after the last amino acid of FtsQ. We examined the extent of biotinylation of FtsQ-PSBT in wild-type HPT242 and the strongest ffs mutant HPT244 (ffs69) expressing this construct from pHP42. A similar biotinylation pattern to that of the MalF-PSBT fusions was seen. Although the FtsQ-PSBT remained unbiotinylated in the wild-type strain, the ffs69 mutant accumulated biotinylated FtsQ-PSBT protein (Fig. 5A).
The biotinylatable domain PSBT also was fused to AcrB, an inner membrane protein with 12 transmembrane segments and a member of a membrane complex involved in multidrug resistance (25, 26). PSBT was fused after the 576th amino acid residue of AcrB to generate a periplasmic AcrB-PSBT fusion. Again, the strongest ffs mutant (ffs69 in HPT185) was compared with the wild type (HPT183) for its effect on this polytopic membrane protein expressed from pHP44. As shown in Fig. 5B, whereas AcrB-PSBT remained unbiotinylated in the wild type, the ffs mutant accumulated biotinylated AcrB-PSBT.
In summary, we have demonstrated that the insertion of three topologically different membrane proteins is affected by the ffs mutations, isolated in an in vivo screen for the altered membrane localization of the MalF-LacZ fusion protein.
Discussion
We set out to find new classes of mutations affecting disulfide bond formation. This goal was achieved as we detected additional classes of mutations in the dsbA and dsbB. We also had expected to find mutations affecting cellular components necessary for the reoxidation of DsbB. Recent results have shown that these components, quinones and cytochrome oxidases, are redundant, thereby explaining the failure to detect such mutations in the screen because mutations in multiple genes would be required to generate the phenotype (27, 28). However, an additional class of mutations was found, which, instead of altering disulfide bond formation, affected membrane protein assembly. This finding accomplishes the original purpose of the genetic approach initiated about 10 years ago. Thus, a single genetic screening procedure yields mutations in two distinct major cellular processes.
The isolation of ffs mutations described in this paper shows a genetic search designed to detect mutations affecting membrane protein assembly has yielded mutations involved in the process. These ffs mutant strains present an advantage over those used previously to assess the effects of disrupting SRP components. These earlier studies used either depletion strains or strains expressing dominant mutations so that membrane protein assembly was assayed under conditions where cells were severely affected in growth (11, 13, 16, 18). In such cases, it can be difficult to separate out secondary effects of depletion in cells that have been affected so strongly in their physiology. The ffs mutant strains described here grow either normally or with near-normal growth rates (ffs69). The defects in membrane protein insertion in the ffs mutants are probably weak, as indicated by the low levels of cytoplasmic localization of the MalF-LacZ hybrid. Nevertheless, we were able to overcome this weakness by using a sensitive assay. By attaching a biotinylatable domain to normally exported domains of membrane proteins, one can detect kinetic effects on incorporation of proteins into the membrane. Using this approach, we have shown that MalF, AcrB, and FtsQ at least partly depend on 4.5S RNA for their assembly. ffs69 caused the strongest defect, as represented by the highest amount of biotinylated fusion proteins. We show that the ffs mutants affect membrane proteins with multiple membrane spanning segments as well as with a single membrane spanning segment (FtsQ).
We have seen a strict distinction between the effects of the mutation affecting SecA (the gene X mutation) and the ffs69 mutation on membrane protein assembly vs. protein secretion. Both classes of mutations caused comparable levels of biotinylation of MalF-PBST periplasmic fusions. In contrast, the gene X mutation resulted in a defect in OmpA export to the cell envelope, whereas the ffs mutations did not show such an effect. Furthermore, when PSBT was fused to the periplasmic MalE, the wild-type and the ffs mutants did not show any biotinylated protein whereas the gene X mutant did (data not shown). This experiment also rules out the possibility that ffs mutations affected only biotinylation, not membrane protein insertion. Although secA has been shown to be involved in the insertion of some inner membrane proteins but not others (12, 15, 17, 19, 29–31), our result suggests that SecA is at least partially required for the insertion of MalF.
We suspect that the clustering of ffs mutations in strings of cytosines near the 3′ is a result of the UV mutagenesis, which tends to affect adjacent pyrimidine-pyrimidine pairs (32). A pyrimidine-rich stretch such as that at the 3′ end of 4.5S RNA (see Fig. 2) may represent a mutational hot-spot for UV (33). The fact that we obtained 25 ffs mutations in this screen and only one in the secA region (gene X in this case), which presents a much larger target, is consistent with this interpretation, as is the absence of mutations in ffh, ftsY, and other sec genes. Characterization of a larger number of mutants or use of other mutagens may yield mutations in these other genes.
We hypothesize that the mutations in ffs cause membrane protein insertion defects by reducing the amount of mature 4.5S RNA. The degree of reduction of mature 4.5S RNA in the mutants correlated with the defect in membrane protein assembly as measured by the biotinylation assay. We assume that the unprocessed 4.5S RNA is nonfunctional or does not function as well as the processed form. Alternatively, the alterations of the 4.5S RNA may interfere with its function. For example, the mutated nucleotides could be involved in interaction with either the polypeptide to be targeted to the membrane or the Ffh protein itself. However, previous in vitro experiments had indicated that the region in 4.5S RNA interacting with the Ffh protein is the central stem-loop region, which is conserved across species (34). Recent crystal structure studies of the 4.5S RNA and Ffh complex also support this observation (35).
Finally, our results suggest why we were unable to obtain mutants affected in membrane protein assembly in the original selection. The selection for Lac+ derivatives of the malF-lacZ fusion strain required high levels of restoration of the β-galactosidase activity. Mutations of such severity in membrane protein assembly probably would have resulted in membranes devoid of a substantial fraction of their proteins and would likely have been lethal. Indeed, our ffs mutants are found only among those with weak effects on the malF-lacZ fusion. Furthermore, among these weak mutants, the strongest ffs69 mutant already shows a slight growth defect. We suspect that mutations with significantly stronger defects would not be viable.
Acknowledgments
We thank Harris D. Bernstein, Jan-Willem De Gier, Annick Jacq, Hiroshi Nikaido, Donald B. Oliver, Daniel Ritz, and David S. Weiss for the provision of antibody, strains, and plasmids. We gratefully acknowledge helpful advice given by Laurent Debarbieux, George Jander, Jennifer A. Leeds, and Daniel Ritz. This work was supported by National Institutes of Health Grant GM38922 (to J.B.). J.B. is an American Cancer Society Research Professor.
Abbreviations
- SRP
signal recognition particle
- X-Gal
5-bromo-4-chloro-3-indolyl β-d-galactopyranoside
- PSBT
Propionibacterium shermania transcarboxylase
Footnotes
Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.090087297.
Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.090087297
References
- 1.Froshauer S, Green G N, Boyd D, McGovern K, Beckwith J. J Mol Biol. 1988;200:501–511. doi: 10.1016/0022-2836(88)90539-6. [DOI] [PubMed] [Google Scholar]
- 2.McGovern K, Beckwith J. J Biol Chem. 1991;266:20870–20876. [PubMed] [Google Scholar]
- 3.Bardwell J C, McGovern K, Beckwith J. Cell. 1991;67:581–589. doi: 10.1016/0092-8674(91)90532-4. [DOI] [PubMed] [Google Scholar]
- 4.Grauschopf U, Winther J R, Korber P, Zander T, Dallinger P, Bardwell J C. Cell. 1995;83:947–955. doi: 10.1016/0092-8674(95)90210-4. [DOI] [PubMed] [Google Scholar]
- 5.Bardwell J C A, Lee J-O, Jander G, Martin N, Belin D, Beckwith J. Proc Natl Acad Sci USA. 1993;90:1038–1042. doi: 10.1073/pnas.90.3.1038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jander G, Cronan J E, Jr, Beckwith J. J Bacteriol. 1996;178:3049–3058. doi: 10.1128/jb.178.11.3049-3058.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Miller J H. Experiments in Molecular Genetics. Plainview, NY: Cold Spring Harbor Lab. Press; 1972. [Google Scholar]
- 8.Rajagopalan K V, Johnson J L. J Biol Chem. 1992;267:10199–10202. [PubMed] [Google Scholar]
- 9.Rech S, Deppenmeier U, Gunsalus R P. J Bacteriol. 1995;177:1023–1029. doi: 10.1128/jb.177.4.1023-1029.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Pogliano K J, Beckwith J. Genetics. 1993;133:763–773. doi: 10.1093/genetics/133.4.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.De Gier J W L, Mansournia P, Valent Q A, Phillips G J, Luirink J, von Heijne G. FEBS Lett. 1996;399:307–309. doi: 10.1016/s0014-5793(96)01354-3. [DOI] [PubMed] [Google Scholar]
- 12.Gebert J F, Overhoff B, Manson M D, Boos W. J Biol Chem. 1988;263:16652–16660. [PubMed] [Google Scholar]
- 13.Macfarlane J, Muller M. Eur J Biochem. 1995;233:766–771. doi: 10.1111/j.1432-1033.1995.766_3.x. [DOI] [PubMed] [Google Scholar]
- 14.Newitt J A, Bernstein H D. J Biol Chem. 1998;273:12451–12456. doi: 10.1074/jbc.273.20.12451. [DOI] [PubMed] [Google Scholar]
- 15.Qi H Y, Bernstein H D. J Biol Chem. 1999;274:8993–8997. doi: 10.1074/jbc.274.13.8993. [DOI] [PubMed] [Google Scholar]
- 16.Seluanov A, Bibi E. J Biol Chem. 1997;272:2053–2055. doi: 10.1074/jbc.272.4.2053. [DOI] [PubMed] [Google Scholar]
- 17.Traxler B, Murphy C. J Biol Chem. 1996;271:12394–12400. doi: 10.1074/jbc.271.21.12394. [DOI] [PubMed] [Google Scholar]
- 18.Ulbrandt N D, Newitt J A, Bernstein H D. Cell. 1997;88:187–196. doi: 10.1016/s0092-8674(00)81839-5. [DOI] [PubMed] [Google Scholar]
- 19.Wolfe P B, Rice M, Wickner W. J Biol Chem. 1985;260:1836–1841. [PubMed] [Google Scholar]
- 20.Schmidt M G, Rollo E E, Grodberg J, Oliver D B. J Bacteriol. 1988;170:3404–3414. doi: 10.1128/jb.170.8.3404-3414.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Schmidt M G, Oliver D B. J Bacteriol. 1989;171:643–649. doi: 10.1128/jb.171.2.643-649.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Rajapandi T, Dolan K M, Oliver D B. J Bacteriol. 1991;173:7092–7097. doi: 10.1128/jb.173.22.7092-7097.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Poritz M A, Strub K, Walter P. Cell. 1988;55:4–6. doi: 10.1016/0092-8674(88)90003-7. [DOI] [PubMed] [Google Scholar]
- 24.Carson M J, Barondess J, Beckwith J. J Bacteriol. 1991;173:2187–2195. doi: 10.1128/jb.173.7.2187-2195.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ma D, Cook D N, Alberti M, Pon N G, Nikaido H, Hearst J E. J Bacteriol. 1993;175:6299–6313. doi: 10.1128/jb.175.19.6299-6313.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Okusu H, Ma D, Nikaido H. J Bacteriol. 1996;178:306–308. doi: 10.1128/jb.178.1.306-308.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bader M, Muse W, Ballou D P, Gassner C, Bardwell J C. Cell. 1999;98:217–227. doi: 10.1016/s0092-8674(00)81016-8. [DOI] [PubMed] [Google Scholar]
- 28.Kobayashi T, Ito K. EMBO J. 1999;18:1192–1198. doi: 10.1093/emboj/18.5.1192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Bassilana M, Gwizdek C. EMBO J. 1996;15:5202–5208. [PMC free article] [PubMed] [Google Scholar]
- 30.Scotti P A, Valent Q A, Manting E H, Urbanus M L, Driessen A J, Oudega B, Luirink J. J Biol Chem. 1999;274:29883–29888. doi: 10.1074/jbc.274.42.29883. [DOI] [PubMed] [Google Scholar]
- 31.Werner P K, Saier M H, Jr, Muller M. J Biol Chem. 1992;267:24523–24532. [PubMed] [Google Scholar]
- 32.Todd P A, Glickman B W. Proc Natl Acad Sci USA. 1982;79:4123–4127. doi: 10.1073/pnas.79.13.4123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sage E, Cramb E, Glickman B W. Mutat Res. 1992;269:285–299. doi: 10.1016/0027-5107(92)90211-j. [DOI] [PubMed] [Google Scholar]
- 34.Wood H, Luirink J, Tollervey D. Nucleic Acids Res. 1992;20:5919–5925. doi: 10.1093/nar/20.22.5919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Batey R T, Rambo R P, Lucast L, Rha B, Doudna J A. Science. 2000;287:1232–1239. doi: 10.1126/science.287.5456.1232. [DOI] [PubMed] [Google Scholar]
- 36.Singer M, Baker T A, Schnitzler G, Deischel S M, Goel M, Dove W, Jaacks K J, Grossman A D, Erickson J W, Gross C A. Microbiol Rev. 1989;53:1–24. doi: 10.1128/mr.53.1.1-24.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Pogliano J, Lynch A S, Belin D, Lin E C, Beckwith J. Genes Dev. 1997;11:1169–1182. doi: 10.1101/gad.11.9.1169. [DOI] [PubMed] [Google Scholar]
- 38.Rietsch A, Belin D, Martin N, Beckwith J. Proc Natl Acad Sci USA. 1996;93:13048–13053. doi: 10.1073/pnas.93.23.13048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Gil D, Bouche J P. Gene. 1991;105:17–22. doi: 10.1016/0378-1119(91)90508-9. [DOI] [PubMed] [Google Scholar]
- 40.Guzman L M, Belin D, Carson M J, Beckwith J. J Bacteriol. 1995;177:4121–4130. doi: 10.1128/jb.177.14.4121-4130.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Boyd D, Weiss D S, Chen J C, Beckwith J. J Bacteriol. 2000;182:842–847. doi: 10.1128/jb.182.3.842-847.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Guzman L M, Weiss D S, Beckwith J. J Bacteriol. 1997;179:5094–5103. doi: 10.1128/jb.179.16.5094-5103.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Grana D, Gardella T, Susskind M M. Genetics. 1988;120:319–327. doi: 10.1093/genetics/120.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]